IFF Unveils Its Controlled Release Platform Featuring Its Innovation and Trailblazing Excipients

Rhea-AI Summary

On May 15, 2024, IFF (NYSE: IFF), a global leader in various consumer markets, announced the launch of a new controlled release platform. This platform includes their established products METHOCEL™, ETHOCEL™, and POLYOX™. Marketed under the slogan, 'Timing is Everything,' this initiative aims to enhance pharmaceutical therapies by improving the controlled release of active ingredients, thereby boosting patient compliance. The platform also offers educational resources and access to subject matter experts. Jason Hunt, IFF's global strategic marketing manager, highlighted the company's commitment to supporting pharmaceutical formulators and accelerating therapeutic innovations to the market.

Positive

• Launch of a new controlled release platform enhancing product portfolio.
• Inclusion of established products METHOCEL™, ETHOCEL™, and POLYOX™.
• Platform aimed at improving patient compliance through better active ingredient release.
• Educational resources and expert access provided for partners.
• Commitment to accelerating therapeutic innovations to market.

Negative

• No immediate financial data or impact on revenue reported.
• Potential high costs associated with the development and implementation of educational resources and expert access.

IFF Pharma Solutions will shine a light on its technology advancements through its flagship products that demonstrate how timing is everything

NEW YORK, May 15, 2024 /PRNewswire/ -- IFF (NYSE: IFF), a global leader in food and beverage, home and personal care and health, today announced a new controlled release platform for its portfolio of controlled release products including METHOCEL™, ETHOCEL™, and POLYOX™.  Under the banner, "Timing is Everything," the platform provides comprehensive solutions for pharmaceutical therapies to benefit patients and highlights the importance of controlled release of active ingredients and improving patient compliance. Complete with educational materials for partners, resources, and access to subject matter experts, the platform can be found at https://pharma.iff.com/controlled-release-platform, where you can also register for an upcoming complimentary educational webinar.

"We are excited to launch the 'Timing is Everything' platform, celebrating our portfolio of controlled release products, to further support pharmaceutical formulators and continue providing more effective options for patients," said Jason Hunt, global strategic marketing manager, IFF Pharma Solutions. "Our experience, knowledge and aptitude for problem-solving help ensure our partners' therapeutic innovations get to market faster."

About Controlled Release

Controlled release formulations are particularly beneficial when specificity is needed, including reduced dosing frequency, enhanced safety profiles, and minimized side effects. These benefits contribute to better patient compliance and treatment adherence. As a result, controlled release dosage forms continue to gain prominence as one of the most dynamic delivery systems in the pharmaceutical landscape.

For over 70 years, IFF Pharma Solutions has been a trailblazer in the controlled release domain, continually introducing groundbreaking products that redefine the standards of drug delivery. The company's signature offerings — METHOCEL™, ETHOCEL™, and POLYOX™ — have not only laid the groundwork for the sector but also persist in propelling forward-thinking solutions to meet intricate drug delivery demands.

METHOCEL™ — Pioneering Then, Innovating Now

In a steadfast commitment to innovation, METHOCEL™ cellulose ethers remain the top choice for controlled-release matrix formulations. Offering a versatile range of methylcellulose (MC) and hydroxypropyl methylcellulose (HPMC) products, METHOCEL™ caters to a broad spectrum of formulation characteristics. With a long-standing history of reliability in pharmaceutical applications, it continues to deliver unparalleled efficacy in both solid and liquid dosage forms.

ETHOCEL™ — Proven Time After Time

ETHOCEL™ ethylcellulose polymer products are distinguished by their organosolubility, precise specification ranges, and uniform ethoxyl functionality. Renowned as the polymer of choice for coating multi-particulates, ETHOCEL™ is indispensable for attaining modified release and superior taste-masking in various pharmaceutical applications.

POLYOX™ — Versatile Across Complex and Unique Applications

POLYOX™ polyethylene oxide products are recognized for their pivotal role in osmotic pump delivery systems and are equally adept in specialty matrices that demand distinctive characteristics such as high swelling, mucoadhesion, abuse deterrence, and exceptional mechanical strength.

"We are proud to help customers find answers at every turn," said Paula Garcia Todd, global applications, development and innovation director, IFF Pharma Solutions. "Our passion for perfecting technologies for controlled release—to help improve the quality of patients' lives— drives us to innovate. As we celebrate our history of leadership, and plan future innovative solutions, we remain focused on what we call our 'everyday innovations.' From METHOCEL™ to ETHOCEL™ and POLYOX™, our products offer customized solutions for various release profiles."

IFF Pharma Solutions will host a webinar titled, "Controlled Release Redefined: The Strategic Use of Excipients in Formulation" on June 12, 2024. The webinar will cover the nuances of controlled release formulations, the influence of excipient physiochemical properties on release performance, and how strategic choices in these properties can help formulators develop distinct controlled release delivery systems. To register, please sign up at the link.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partner with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.  Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn. 

©2024 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contact:

Lisa Luke
Global Communications Director
+1 302-927-9234
lisa.luke@iff.com 

SOURCE IFF

FAQ

What is IFF's new controlled release platform?

IFF's new controlled release platform, launched on May 15, 2024, includes products like METHOCEL™, ETHOCEL™, and POLYOX™ under the slogan 'Timing is Everything.'

How does the controlled release platform benefit pharmaceutical therapies?

The platform improves the controlled release of active ingredients, enhancing patient compliance and providing effective therapeutic options.

What products are included in IFF's new platform?

IFF's new platform includes METHOCEL™, ETHOCEL™, and POLYOX™ as part of its controlled release solutions.

Where can I find more information about IFF's controlled release platform?

More information about IFF's controlled release platform can be found at https://pharma.iff.com/controlled-release-platform.

What additional resources does IFF offer through the new platform?

IFF offers educational materials, resources, and access to subject matter experts through its new controlled release platform.